uniQure (QURE) Misses Q3 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/26/2026
Go back to uniQure (QURE) Misses Q3 EPS by 3c
December 1, 2015 9:49 AM EST
Jefferies analyst, Eun Yang, reduced the price target on uniQure BV (NASDAQ: QURE) to $36 vs $40 previously. The drop takes into account the loss of revenue from the removal of Glybera and increasing the discount rate to 13% (from 12%) to reflect yet-to-be proven commercial potential/success of gene therapy products. No change to... More
December 1, 2015 7:11 AM EST
Oppenheimer Christopher Marai views yesterday's nearly 17% sell-off in uniQure BV (NASDAQ: QURE) unfounded. As such, the firm reiterated an Outperform rating and price target of $50.
uniQure reported 3Q15, ending the quarter with $215M in cash.
Marai commented, "Importantly, QURE clarified the... More
November 30, 2015 7:44 AM EST
Cowen analyst Ritu Baral reiterated an Outperform rating on uniQure BV (NASDAQ: QURE) Ph1/2 12 mo. MPS3b AMT-110 data was presented again at ICSS Friday and was very well received by MPS3 KOLs.
Baral commented, "The trial PI noted 18 more mos. of... More
